{"product_id":"daiichisankyo-swot-analysis","title":"Daiichi Sankyo SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDaiichi Sankyo’s robust R\u0026amp;D pipeline and global partnerships position it well for long-term growth, while patent cliffs and pricing pressures pose real challenges; regulatory scrutiny and competition could reshape near-term prospects. Purchase the full SWOT analysis to access an investor-ready, research-backed report with editable Word and Excel deliverables—perfect for strategy, due diligence, or investment planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance in ADC Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary DXd antibody-drug conjugate (ADC) platform remains Daiichi Sankyo’s core advantage through late 2025, enabling high drug-to-antibody ratios (up to ~8:1) and a topoisomerase I payload that boosts tumor kill while cutting systemic toxicity versus older ADCs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with AstraZeneca\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe long-term alliance with AstraZeneca for Enhertu and datopotamab deruxtecan has expanded Daiichi Sankyo’s global reach, adding AstraZeneca’s 2024 US sales force and European channels and boosting potential peak sales—Analyst consensus 2025 combined TAM for HER2 and TROP2 ADCs ~USD 15–20bn. \u003c\/p\u003e\n\u003cp\u003eShared commercial infrastructure and oncology R\u0026amp;D cut Daiichi Sankyo’s net commercialization spend; co-funded trials increased phase 3 starts by 40% in 2023–24, accelerating US\/EU market penetration. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Value Oncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo has shifted from primary care to oncology, with Enhertu (trastuzumab deruxtecan) driving revenue—global sales reached ¥462.5 billion (about $3.1B) in FY2024 H1 to Sept 30, 2024—lifting group margins and EPS. Enhertu set new standards for HER2-positive cancers, expanding indications and supporting double-digit year-on-year growth. The oncology pivot improved institutional investor sentiment and provides a high-margin base for future earnings and pipeline valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpdaiichi sankyo decentralized but integrated r network taps global talent and diverse patient pools supporting active clinical trials across countries as of cutting time-to-proof-of-concept by after facility upgrades.\u003e\u003cpinvestment in modern labs and data platforms helped move new molecular entities into clinical development fueling a pipeline that underpins projected mid-single-digit revenue cagr to\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45+ active trials, 20 countries\u003c\/li\u003e\n\u003cli\u003e~18% faster PoC\u003c\/li\u003e\n\u003cli\u003e6 NME entrants (2024–2025)\u003c\/li\u003e\n\u003cli\u003eSupports mid-single-digit CAGR to 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pinvestment\u003e\u003c\/pdaiichi\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpdaiichi sankyo holds solid finances into with fy2024 revenue trillion and operating cash flow boosted by oncology cardiovascular sales enabling billion annual r spending.\u003e\u003cpthis liquidity funds multiple phase programs internally and supports targeted biotech buys keeping net debt near reducing dependence on external financing.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue ~¥1.04T\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend ¥150–200B\/year\u003c\/li\u003e\n\u003cli\u003enet debt\/EBITDA ≈0.5x\u003c\/li\u003e\n\u003cli\u003eself-funds Phase 3, enables bolt-on M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pdaiichi\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhertu-fueled oncology growth: ¥1.04T revenue, ¥462.5B H1 sales, 45+ trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary DXd ADC platform (DAR ~8, topo I payload) and Enhertu partnership with AstraZeneca drive strong oncology franchise; Enhertu FY2024 H1 sales ¥462.5B (~$3.1B).\u003c\/p\u003e\n\u003cp\u003e45+ active trials in 20 countries, 6 NMEs entered 2024–25, PoC time cut ~18%; FY2024 revenue ~¥1.04T, R\u0026amp;D ¥150–200B, net debt\/EBITDA ≈0.5x.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu H1 FY2024 sales\u003c\/td\u003e\n\u003ctd\u003e¥462.5B (~$3.1B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e¥1.04T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive trials \/ countries\u003c\/td\u003e\n\u003ctd\u003e45+ \/ 20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew clinical entrants 2024–25\u003c\/td\u003e\n\u003ctd\u003e6 NME\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e¥150–200B\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e≈0.5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT analysis of Daiichi Sankyo, outlining its core strengths, operational weaknesses, market opportunities, and external threats to clarify strategic priorities and competitive positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Daiichi Sankyo SWOT snapshot for rapid strategic alignment and clear stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Dependence on Enhertu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Daiichi Sankyo’s market value and 2024 revenue growth stems from Enhertu (trastuzumab deruxtecan); Daiichi holds a ~50% stake in global profits via the AstraZeneca\/Japan JV, and Enhertu sales reached $7.4 billion in 2024, driving most of the company’s upward revisions.\u003c\/p\u003e\n\u003cp\u003eAny safety signals or regulatory delays in new indications—breast, lung, gastric—could cut projected EPS and cash flow sharply; a single adverse label change historically trims biotech peers’ valuations by 20–40%.\u003c\/p\u003e\n\u003cp\u003eDiversifying beyond this antibody–drug conjugate (ADC) is urgent: Daiichi’s 2024 R\u0026amp;D pipeline shows several early\/Phase II oncology assets but limited late‑stage non‑ADC programs, leaving concentration risk high for long‑term stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpcoming Patent Expirations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaiichi Sankyo faces imminent patent expirations—most notably Lixiana (edoxaban) losing exclusivity in key markets by 2026—risking a revenue gap after Lixiana contributed ~¥120 billion in 2023 sales. These patent cliffs force rapid reliance on oncology launches like mobocertinib and DS-1062 to replace volume primary-care income. Transitioning shifts margins: specialty oncology typically raises gross margin variance and R\u0026amp;D intensity, so managing cash flow and pricing will be critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational and R\u0026amp;D Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpthe complexity of antibody-drug conjugate development and manufacturing drives daiichi sankyo operating expenses well above small-molecule peers capex cmc controls costs can be higher per program.\u003e\n\u003cpextensive global trials for adcs routinely enroll thousands of patients daiichi sankyo reported r spend billion in fy2024 reflecting these large costly programs.\u003e\n\u003cpmaintaining heavy r and manufacturing outlays is essential for pipeline progress but delayed trial readouts or regulatory setbacks can meaningfully pressure short-term profitability free cash flow.\u003e\n\u003c\/pmaintaining\u003e\u003c\/pextensive\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Complexity of ADCs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe production of antibody-drug conjugates is a three-part highly specialized process linker and cytotoxic payload any supply-chain disruption can cause major delays daiichi sankyo reported adc-related manufacturing investments about billion in to scale capacity.\u003e\u003cpscaling globally raises risk: technical failures or batch losses can cut yields by double digits and delay launches impacting revenue streams tied to mid-to-late stage adcs.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThree-part process: antibody, linker, payload\u003c\/li\u003e\n\u003cli\u003e¥40B (≈$280M) 2024 investment\u003c\/li\u003e\n\u003cli\u003eSupply-chain disruption → significant bottlenecks\u003c\/li\u003e\n\u003cli\u003eScaling risk: batch losses can reduce yields by 10%+\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pscaling\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Revenue Imbalance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdespite a growing global presence about of daiichi sankyo fy2024 revenue came from japan and north america leaving the firm exposed to regional shocks like drug price revisions cuts averaging in recent years potential us healthcare reform.\u003e\u003cpexpanding sales in emerging markets cagr for pharma was diversify risk and reduce sensitivity to localized regulatory shifts.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% revenue from Japan + North America (FY2024)\u003c\/li\u003e\n\u003cli\u003eJapan drug-price revisions: ~1–2% annual impact\u003c\/li\u003e\n\u003cli\u003eEmerging markets pharma growth: ~6–8% CAGR (2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pexpanding\u003e\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration risk: Enhertu reliance, Lixiana patent cliffs, high ADC costs and regional focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on Enhertu (~50% profit share via JV; $7.4B sales in 2024) and upcoming Lixiana patent expiries (key markets by 2026; Lixiana ≈¥120B sales in 2023) create concentration and revenue‑replacement risk; high ADC R\u0026amp;D\/manufacturing costs (¥200.3B R\u0026amp;D FY2024; ¥40B ADC capex 2024) plus supply‑chain\/scale risks and regional revenue concentration (~70% Japan+NA) weaken resilience.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$7.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJV profit share\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e¥200.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADC capex 2024\u003c\/td\u003e\n\u003ctd\u003e¥40B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLixiana 2023 sales\u003c\/td\u003e\n\u003ctd\u003e¥120B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Japan+NA\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eDaiichi Sankyo SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is a real excerpt from the complete Daiichi Sankyo SWOT analysis document—the same file you'll receive after purchase, professionally structured and editable for your use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752728113529,"sku":"daiichisankyo-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/daiichisankyo-swot-analysis.png?v=1772244458","url":"https:\/\/matrixbcg.com\/products\/daiichisankyo-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}